Literature DB >> 14607083

RAMPs: 5 years on, where to now?

Maria Morfis1, Arthur Christopoulos, Patrick M Sexton.   

Abstract

It is now approximately 5 years since the identification of the family of receptor activity modifying proteins (RAMPs). This finding revolutionized concepts of the pharmacology of G-protein-coupled receptors (GPCRs) and revealed that GPCR accessory proteins not only assist trafficking and folding but also define receptor type. Since the identification of RAMPs as modulators of the trafficking and properties of the calcitonin-receptor-like receptor, much work has focused on improving our understanding of the nature of RAMP-GPCR dimers, the extent to which they occur, and the consequence of this association. In this article, we review recent developments, including the identification of new receptor partners and novel roles for RAMPs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607083     DOI: 10.1016/j.tips.2003.09.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  17 in total

1.  Mutational and cysteine scanning analysis of the glucagon receptor N-terminal domain.

Authors:  Martine Prévost; Pascale Vertongen; Vincent Raussens; David Jonathan Roberts; Johnny Cnudde; Jason Perret; Magali Waelbroeck
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

2.  A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor.

Authors:  Freddy Jeanneteau; Benoît Funalot; Joseph Jankovic; Hao Deng; Jean-Pierre Lagarde; Gérard Lucotte; Pierre Sokoloff
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-29       Impact factor: 11.205

3.  Heterodimerization and surface localization of G protein coupled receptors.

Authors:  Kenneth P Minneman
Journal:  Biochem Pharmacol       Date:  2006-09-09       Impact factor: 5.858

4.  The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity.

Authors:  Yuka Ichikawa-Shindo; Takayuki Sakurai; Akiko Kamiyoshi; Hisaka Kawate; Nobuyoshi Iinuma; Takahiro Yoshizawa; Teruhide Koyama; Junichi Fukuchi; Satoshi Iimuro; Nobuo Moriyama; Hayato Kawakami; Toshinori Murata; Kenji Kangawa; Ryozo Nagai; Takayuki Shindo
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 5.  Peptide-Liganded G Protein-Coupled Receptors as Neurotherapeutics.

Authors:  Lee E Eiden; Ki Ann Goosens; Kenneth A Jacobson; Lorenzo Leggio; Limei Zhang
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

6.  Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner.

Authors:  Cordelia J Barrick; Patricia M Lenhart; Ryan T Dackor; Elizabeth Nagle; Kathleen M Caron
Journal:  J Mol Cell Cardiol       Date:  2011-11-04       Impact factor: 5.000

7.  Identification of RL-TGR, a coreceptor involved in aversive chemical signaling.

Authors:  Staci P Cohen; Karla K V Haack; Gwyneth E Halstead-Nussloch; Karen F Bernard; Hanns Hatt; Julia Kubanek; Nael A McCarty
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

Review 8.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

9.  Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor.

Authors:  Kaleeckal G Harikumar; John Simms; George Christopoulos; Patrick M Sexton; Laurence J Miller
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

10.  Allosteric modulators of class B G-protein-coupled receptors.

Authors:  Sam R J Hoare
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.